flomoxef

01/01/2018 - "Patients with Enterobacteriaceae bacteremia who received flomoxef had a lower 30-day crude mortality when the flomoxef MICs of the isolates were ≤1 mg/L than those with MICs ≥2 mg/L."
01/01/2018 - "Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia."
11/01/2014 - "Outcome was determined by mortality resulting from bacteremia during the 14-day period after the collection of the first positive blood culture for flomoxef-susceptible ESBL-Kp. "
09/05/2012 - "Outcome was determined by mortality resulting from bacteremia during the 14-day period after the first positive blood culture for flomoxef-susceptible ESBL-Kp. "
11/01/2014 - "Among patients with catheter-related bacteremia, multivariate analyses revealed that flomoxef use (odds ratio (OR) 2.52, 95% confidence interval (CI) 1.34-35.17) and Pitt bacteremia score (OR 4.37, 95% CI 1.28-5.26) were independently associated with mortality. "

01/01/2018 - "Flomoxef is potentially effective against β-lactamase-producing Enterobacteriaceae because limited clinical data demonstrate its effectiveness against Enterobacteriaceae bloodstream infections (BSIs) based on its minimum inhibitory concentrations (MICs). "
01/01/2018 - "Flomoxef is effective against CE in vitro, and some clinical data on its demonstrated effectiveness against CE bloodstream infections (BSIs) exists. "
12/01/2015 - "The sepsis-related mortality rate of the flomoxef group increased to 29.6% and 50.0% of episodes caused by isolates with a MICflomoxef of 2-4 mg/L and 8 mg/L, respectively, which was significantly higher than the carbapenem group (12.3%). "
12/01/2015 - "The flomoxef group had statistically significantly higher sepsis-related mortality (27.3% vs. 10.5%) and 30-day mortality (28.8% vs. 12.8%) than the carbapenem group. "
05/01/1996 - "The results of this study demonstrated that flomoxef is a safe and effective antimicrobial agent in the treatment of patients with sepsis and/or Gram-negative bacteremia."

06/01/1991 - "[Clinical studies on flomoxef in the perinatal period infections]."
06/01/1991 - "[Clinical studies on flomoxef in pregnant women with infections during the perinatal period]."
10/01/1987 - "[Clinical studies on flomoxef in respiratory infection]."
12/01/2015 - "Whether flomoxef may be used for the treatment of such infections remains controversial. "
05/01/2015 - "In conclusion, flomoxef showed good activity against ESBL-producing Enterobacteriaceae and may be a choice to treat infections caused by these isolates in China. "

10/01/1987 - "[Clinical trials of flomoxef in complicated urinary tract infections]."
02/11/2021 - "In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Associated with Urinary Tract Infections in Malaysia."
03/28/2022 - "The optimal regimens of cefmetazole and flomoxef for the treatment of urinary tract infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales are not well defined. "
03/28/2022 - "Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function."
10/01/1987 - "Flomoxef (6315-S, FMOX), a new oxacephem antibiotic was studied clinically in 27 patients with complicated urinary tract infections. "

05/01/1988 - "[Clinical trials of flomoxef in patients with chronic respiratory tract infections]."
10/01/1987 - "[Clinical studies on flomoxef in respiratory tract infections]."
10/01/1987 - "[A study on flomoxef against respiratory infections in the aged]."
05/01/1988 - "Flomoxef (FMOX, 6315-S), a newly developed oxacephem drug, was administered to 6 patients with chronic respiratory tract infections. "
10/01/1987 - "Flomoxef (FMOX, 6315-S), a new antibacterial drug, was administered to 9 cases with respiratory tract infections for a duration of 8 approximately 16 days at a daily dose of 2 g. "